SPY337.59-8.19 -2.37%
DIA275.45-7.89 -2.78%
IXIC11,289.68-258.60 -2.24%

AzurRx BioPharma Activates Additional Clinical Trial Sites In Turkey For Phase 2 Combination Therapy Trial Of MS1819 In Cystic Fibrosis

Two clinical trial sites activated in Turkey, with patient screening initiated Follows activation of six clinical sites in Hungary and dosing of first eight patients Topline data expected

· 10/14/2020 08:08
  • Two clinical trial sites activated in Turkey, with patient screening initiated
  • Follows activation of six clinical sites in Hungary and dosing of first eight patients
  • Topline data expected in Q2 2021


     

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has activated two trial sites in Turkey for its Phase 2 Combination Therapy clinical trial to investigate MS1819 in cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI). A total of eight of the expected twelve sites in Europe are now active and recruiting patients.

"We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial," said Dr. James Pennington, Chief Medical Officer of AzurRx. "The recently reported interim data suggests promising results and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the start-up of this trial in a very efficient and effective manner, and we look forward to our continued work with them."